Cellebrite Appoints Shiven Ramji Chief Executive Officer, Succeeding Thomas E. Hogan
Cellebrite DI Ltd. (NASDAQ: CLBT) appointed Shiven Ramji as CEO, replacing Thomas E. Hogan, effective immediately. The company reported Q2 2026 results: ARR $507.8M (+21% YoY), revenue $131.1M (+16% YoY), GAAP net income $6.4M. It lowered FY2026 ARR and revenue outlook but raised adjusted EBITDA target, citing longer sales cycles and weaker Inseyets expansion.
How this was made
The 30-second read
Why it matters
The combination of an immediate CEO change and a quantified guidance reset is likely to drive repricing around execution quality, sales-cycle duration, and the sustainability of margin expansion.
Market read
Traders get a same-day catalyst: Q2 print with ARR/revenue dynamics plus explicit FY26 ARR and revenue downside, offset by a higher adjusted EBITDA target.
What to watch
The article highlights execution actions and measured near-term contribution from newer products, which could mean the lowered outlook is conservative rather than deteriorating fundamentals; also, raised adjusted EBITDA target implies cost discipline that may reduce downside volatility.
Background
Cellebrite is transitioning from Thomas E. Hogan to Shiven Ramji (effective immediately) while reporting Q2 2026 results and revising FY26 guidance.
Ticker impact
Cellebrite appointed Shiven Ramji as CEO and reported Q2 results while lowering FY26 ARR and revenue outlook, raising adjusted EBITDA target.
Likely choppy-to-negative near term on the lowered ARR/revenue outlook, partially offset by the raised adjusted EBITDA target and ongoing product momentum.
The article contains primary disclosures: immediate CEO succession and quantified Q2 performance plus explicit FY26 outlook changes (lower ARR/revenue, higher adjusted EBITDA). Traders will reprice growth versus profitability tradeoffs and execution risk (longer sales cycles, weaker Inseyets expansion).
Market effects
Digital forensics and investigative AI vendors may see read-across on enterprise/government sales-cycle length and conversion rates, especially for SaaS evidence management.
Management cites healthy growth in Asia-Pacific, EMEA, and U.S. Federal, suggesting regional demand resilience despite overall ARR shortfall.
Guidance reset can influence sentiment toward public-sector AI/forensics procurement pipelines and budgeting for 2H26.
Counterpoint
The ARR miss may be timing-related (longer sales cycles, conversion expansion slower) while product adoption (Genesis monetization, FedRAMP High for Guardian) could support a stronger 2H26 inflection.
Key entities
- companyCellebrite DI Ltd.
NASDAQ-listed digital investigative and intelligence solutions provider reporting Q2 results and revising FY26 outlook.
- personShiven Ramji
Appointed CEO effective immediately; previously President, Products and Technology since May 2026.
- personThomas E. Hogan
Outgoing CEO, previously interim CEO and CEO since Aug 2025, now Executive Chairman.
- personDavid Barter
CFO discussing outlook and second-half free cash flow expectations.
